Capital World Investors
TGTX icon

Capital World Investors’s TG Therapeutics TGTX Stock Holding History

Capital World Investors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,172,153
Closed -$79.3M – 614
2021
Q4 		$79.3M Buy
4,172,153
+22
+0% +$571 0.01% 393
2021
Q3 		$139M Buy
4,172,131
+829
+0% +$25.6K 0.02% 340
2021
Q2 		$162M Buy
4,171,302
+1,017,359
+32% +$40M 0.03% 331
2021
Q1 		$152M Buy
3,153,943
+2,303,943
+271% +$111M 0.03% 321
2020
Q4 		$44.2M Buy
+850,000
New +$28.7M 0.01% 421

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Capital World Investors's TGTX Position: Q1 2022 in Review

Capital World Investors sold out of TG Therapeutics (TGTX) in Q1 2022, closing a stake of 4,172,153 shares — an estimated $79.3M sold.

Capital World Investors first reported a position in TGTX in Q4 2020 and held it in 5 quarters. The position peaked at $162M in Q2 2021. 181 funds tracked by Wall St. Rank hold TGTX as of Q1 2022.

  • Capital World Investors reported no remaining TG Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Capital World Investors sold 4,172,153 TG Therapeutics shares in Q1 2022, an estimated $79.3M.
  • Capital World Investors first reported a position in TG Therapeutics in Q4 2020 and held it in 5 quarters.
  • Capital World Investors's TG Therapeutics position peaked at $162M in Q2 2021.
  • 181 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2022.

Based on Capital World Investors's 13F filing for Q1 2022, filed 16 May 2022.